E-GEOD-45405 - Examination of the MAPK pathway gene expression in patient samples
Released on 3 June 2013, last updated on 2 June 2014
Microarray analysis of total RNA isolated from samples of circulating tumor cells from 7 patients before romidepsin infusion (0 hours), at 4 h after initiation of the infusion (4 hours) and 24 h after initiation of the infusion (24 hours). MAPK pathway related genes were selected to see differences between patient blood samples after roomidepsin treatment at 0 hour, 4 hour and 24 hour.
transcription profiling by array
Louise C Showe <firstname.lastname@example.org>, AR Chakraborty, AV Kossenkov, J Gillet, J Wilkerson, LC Showe, MM Gottesman, NL Collie, RL Piekarz, RW Robey, SE Bates, VL Luchenko, Z Zhan
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet JP, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, Collie NL, Bates SE. , Europe PMC 23532732